By Ellen Bown, Contributing Author from the UK
The research leading to HPV vaccine development began in the 1980’s. Currently there are two vaccines on the market worldwide; Gardasil manufactured by Merck Inc. and Cervarix manufactured by GlaxoSmithKline. In September 2008 the government began a mass immunisation programme aimed at all girls in the UK between the ages of 12 – 13, with a catch up programme for girls 14 – 17 years. At the time their vaccination of choice was Cervarix (The government is changing to Gardasil in September 2012). Cervarix is a vaccine which is supposed to prevent early stage cervical cancers i.e. Pre-cancerous lesions and thus prevent cervical cancer caused by the HPV types 16 and 18. However, at the time of the immunization programme being rolled out this vaccine had never been tested on children younger than 15 years. Professor Martina Doren, of the Charitie Hospital in Berlin criticises this fact along with 12 other distinguished professors.1
I have been unable to find any documents stating that tests have now been carried out on this age group. As previously mentioned, protocols are in place to make sure vaccines are safe before being used, but the first question to ask would be; How do we know they are safe to use on this age group when the tests have never been carried out in full?
Furthermore it has been shown by both Merck Inc. and GlaxoSmithKline that if you are already infected by strains 16 and or 18 then the vaccine will not provide you with any protection. If you keep getting infected then the risk of it developing into pre-cancerous lesions may increase by 44.6% after Gardasil and 32.5% after Cervarix. So we may find in a few years, as with smallpox, most cases of cervical cancer are actually caused by the vaccination itself rather than the naturally occurring infection. An infection, let’s remember that in most cases clears itself anyway. Do we want to take that risk?
The ingredients in Cervarix are; active HPV-16 L1 protein and HPV-18 L1 protein, 3-Odesacyl-4’ monophosphoryl lipid A (MPL), aluminium hydroxide, sodium chloride and sodium phosphate-monobasic.
- 3-Odesacyl-4’ monophosphoryl lipid A (MPL) is the adjuvant which is designed to stimulate the body’s immune system. MPL is a derivative of lipid A from Salmonella Minnesota R595. Salmonella is a bacterial infection which lives in the intestinal tract of animals, which is then transmitted to humans by eating foods contaminated by animal faeces causing illness and death.
- Aluminium hydroxide is a protoplasmic poison and a deadly, persistent neurotoxin. “Since 1934, Aluminum Hydroxide has been used as an adjuvant to boost the immune response from vaccines. The effects of poisons can be quick or extremely slow – building gradually up creating low grade debilitation diseases like in chronic fatigue syndrome or devastating neurological disorders like MS, ALS, and Alzheimer’s disease. Though neurodegenerative disorders have several pathways in their creation but nothing will burn up a neuron faster than mercury. This is also the case for aluminum hydroxide, just to a lesser extent. Vancouver neuroscientist Dr. Chris Shaw just finished his research that shows a link between the aluminum hydroxide used in vaccines, and symptoms associated with Parkinson’s, amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), and Alzheimer’s. Autopsy reports on Alzheimer’s patients found 70% more aluminum in the brain.” 2
These are just two of the vaccines ingredients. In 1999 the FDA recommended removing mercury (Thimerosal) from all products, including vaccines and yet aluminium quite clearly has similar effects and is still used.
Would you give your child poison?
- Express.co.uk Sunday May 31st 2009
- IMVA International Medical Veritas Association, http://imva.info/index.php/vaccines/aluminum-hydroxide/